Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 16;35(3):298–305. doi: 10.1038/s41379-021-00913-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — Patterns of pan-TRK IHC expression in NTRK fusion-positive cancers. A A colorectal carcinoma with an LMNA-NTRK1 fusion demonstrates diffuse cytoplasmic expression with accentuation of the nuclear member with pan-TRK immunohistochemistry. The LMNA gene encodes nuclear lamin, which localizes to this area of accentuation. B Pan-TRK immunohistochemistry performed on secretory carcinoma reveals diffuse cytoplasmic and strong (3+) nuclear expression. ETV6 encodes a transcription factor that localizes to the nucleus. Although this case demonstrates diffuse staining, ETV6-NTRK3 fusion-positive cancers often show weak and/or focal pan-TRK expression by immunohistochemistry. C A melanoma with a TRAF2-NTRK2 fusion demonstrates diffuse cytoplasmic and membranous expression on pan-TRK immunohistochemistry. TRAF2 encodes TNF-receptor-associated factor 2, which localizes to the cell membrane.